FDA authorizes intradermal administration of the Jynneos vaccine for the treatment of monkeypox.
The US Food and Drug Administration today authorized intradermal administration of the Jynneos vaccine for the treatment of monkeypox.
The process, approved specifically for high-risk patients, was passed under the administration's Emergency Use Authorization. It follows the decision on August 4 by the US Department of Health and Human Services to declare monkeypox a public health emergency. Intradermal administration will allow providers to get five doses out of a one-dose vial.For more news, follow Medscape on
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
With supplies low, FDA authorizes plan to stretch limited monkeypox vaccine dosesThe Biden administration is allowing the monkeypox vaccine to be given between layers of skin — a method that only requires a fifth of the full dose — in order to increase vaccinations and slow the outbreak.
続きを読む »
FDA authorizes change in how monkeypox vaccine is givenThe US Food and Drug Administration issued an emergency use authorization Tuesday that allows health-care providers to change how the Jynneos monkeypox vaccine is administered, stretching out the supply amid high demand.
続きを読む »
FDA expands monkeypox vaccine authorization to increase dose supply five-foldThe FDA will allow health-care providers to administer the shots through intradermal injection, or between the layers of the skin, for adults.
続きを読む »
FDA Recommends New Monkeypox Vaccine Strategy to Stretch SupplyThe agency is allowing doctors to use a fifth of a normal dose of the Jynneos vaccine
続きを読む »
Protesters demand swifter action as FDA considers plans to split doses of monkeypox vaccineA local infectious disease expert on Monday said she supports the FDA's idea of splitting doses of the monkeypox vaccine to get the shots to more people.
続きを読む »
Amazon sold unauthorized mole removers, and the FDA isn’t happy about itThey’re a health risk.
続きを読む »